Menu
Invent. Lead. Change Lives.
Projects
The Michelson Prize for Human Immunology and Vaccine Research
Recognizing the importance of cultivating new generations of scientists, Michelson Medical Research Foundation partnered with the Human Vaccines Project on the Michelson Prize for Human Immunology and Vaccine Research. Launched in 2018, the prize rewards young investigators from around the world who use disruptive concepts and inventive processes to significantly advance human immunology and vaccine and immunotherapy discovery research for major global diseases.
At the foundation’s annual Conference on the Future of Vaccine Development, Michelson Medical Research Foundation honors the winners of the Michelson Prizes for Human Immunology and Vaccine Research and provides them with a forum for presenting their projects. The event also features engaging expert panels to discuss the latest work in vaccine development.
These prizes give young scientists the freedom to think outside the box. Our collaboration with the Human Vaccines Project in establishing the Michelson Prizes will help unravel the complexity of the human immune system to accelerate development of vaccines and therapies for some of the world’s most threatening diseases.
–Gary Michelson, MD
co-founder,
Michelson Medical Research Foundation
We are honored to be collaborating with the Michelson Medical Research Foundation to implement the visionary commitment of Gary and Alya Michelson of supporting the next generation of scientific leaders on the frontiers of human immunology and vaccine research.
–Wayne Koff, PhD
President and CEO,
Human Vaccines Project
Meet the current and past recipients of the
Michelson Prize for Human Immunology and Vaccine Research.
Congratulations
2020 Michelson Prize Winners
Danika Hill, PhD
Research Fellow
Department of Immunology and Pathology | Monash University, Melbourne, Australia
Dr. Hill is using strep A bacteria to identify the specific antigens that trigger the immunity protections of our bodily fluids. Her innovative strategy potentially opens avenues to improved vaccines for numerous infectious diseases and more effective immunotherapies for cancer.
“The Michelson Prize comes at a critical point in my career,” Dr. Hill says. “With the prize I’ll be able to apply some cutting-edge techniques to study hundreds of thousands of cells in molecular detail.”
Michael Birnbaum, PhD
Assistant Professor
Department of Biological Engineering | MIT
Dr. Birnbaum studies “elite controllers”—those rare individuals with HIV who can go for long periods without antiretroviral therapy—to identify optimal vaccine targets for stopping the virus. While currently focused on HIV, his method can be applied to a range of diseases, from infections to cancer.
“The support provided by this award will let us work faster than would be possible otherwise. We will be trying many of our best ideas at once to press this technology into service, in a time where better tools to study infectious disease are clearly needed,” Dr. Birnbaum says.
2019 Awardees
Murad Mamedov, PhD
Postdoctoral scholar, microbiology and immunology
School of Medicine, University of California, San Francisco
Dr. Mamedov is using gene-editing technologies to create a new platform for understanding an important set of immune cells that may provide the keys to the diagnosis, prevention, and treatment of infectious and noncommunicable diseases such as cancer.
Kamal Mandal, PhD
Postdoctoral scholar, laboratory medicine
School of Medicine, University of California, San Francisco
Dr. Mandal is developing new technologies that identify the shape of proteins that could provide new targets for cancer immunotherapy, with potential applications to other diseases.
Avinash Das Sahu, PhD
Postdoctoral fellow
Department of Data Sciences, Dana-Farber Cancer Institute
Dr. Sahu is building novel artificial intelligence, deep-learning frameworks to devise new therapeutic strategies for cancer immunotherapy, with potential applications to human immunology.
2018 Awardees
Patricia Therese Illing, PhD
Research fellow, biochemistry
and molecular biology
Monash University
Dr. Illing’s work involves a new approach for identifying influenza-specific peptide antigens with implications for the development of vaccines against both seasonal and pandemic influenza strains. The Michelson Prize provided resources to expand her investigations into how viral antigens are recognized by the human immune system.
Laura Kate Mackay, PhD
Laboratory head and senior lecturer
Peter Doherty Institute for Infection and Immunity, University of Melbourne
Dr. Mandal is developing new technologies that identify the shape of proteins that could provide new targets for cancer immunotherapy, with potential applications to other diseases.
Ansuman Satpathy, MD, PhD
Assistant professor
Department of Pathology, Stanford University School of Medicine
Dr. Satpathy’s research focuses on combining the disciplines of genomics and human immunology. He aims to identify key gene regulatory mechanisms that trigger protective immunity following vaccination using novel epigenomic sequencing technologies applied directly to patient samples. The Michelson Prize has allowed him to advance both 3-D and single-cell epigenetic technologies for human immunology and vaccine research.
Partners
USC Michelson Center for Convergent Bioscience
Drawing on the University of Southern California’s tradition of research excellence, the USC Michelson Center for Convergent Bioscience unites scientists and engineers from across the university to promote biomedical innovation and tackle today’s most pressing medical challenges.
Within the walls of the 190,000-square-foot USC Michelson Center on the USC University Park Campus, interdisciplinary collaborators are developing new lifesaving devices and therapeutics—from ways to short-circuit cancer’s development to reducing maternal mortality in childbirth.
Also located within the center are the Bridge Institute, whose goal is to converge knowledge for radical progress in improving the human condition, and the Agilent Center of Excellence in Biomolecular Characterization, a partnership between USC and Agilent to pursue fundamental discoveries in life sciences research.
Gary Michelson shares USC’s commitment to cross-disciplinary discovery and donated $50 million to launch the USC Michelson Center for Convergent Bioscience and its programs.
Physicians Committee for Responsible Medicine
The Physicians Committee for Responsible Medicine (PCRM) promotes the highest ethical standards in medical research and education, advances scientific and technological innovations, and works to eliminate animal experimentation. Today, due in large part to a decades-long campaign by PCRM, 97% of medical schools in the U.S. have replaced the use of animals for medical education with superior and humane alternatives, including human-patient simulators. PCRM also advocates for eliminating the use of animals for product-safety testing.
Past Partners
Sabin Vaccine Institute
Michelson Neglected Disease Vaccine Initiative and Michelson Fund for NTDs Global Awareness
Other Divisions of Michelson Philanthropies
Previous
Next
Media Contact
-
Geoffrey L. Baum
Executive Director - 310.806.9707
- media@michelsonphilanthropy.org
Address
-
11755 Wilshire Boulevard, Suite 1400
Los Angeles, CA 90025
© 2020 Gary K. Michelson